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Opioids comprise an important group of drugs used in cancer pain pharmacotherapy. In recent years, more andmore studies have
emerged indicating the potentially immunosuppressive effects of opioid analgesics and their serious consequences, including the
risk of cancer progression. -e identification of these risks has prompted a search for other effective, and most importantly, safer
methods of perioperative analgesic management. Regional analgesia techniques, which allow for a significant reduction in opioid
dosing and thus diminish the risk of immunosuppression associated with these drugs, seem to offer substantial hope in this
respect. A number of studies available in the literature assess the effects of regional analgesia techniques on cancer progression;
however, it is often difficult to interpret their results owing to several perioperative factors (such as surgical trauma, inadequate
pain and stress relief, and hypothermia) which are also attributed immunosuppressive effects and tend to be implicated in
increased risk of cancer progression. Further research is needed to verify the available data on both the potential adverse effects of
opioids and the possible protective effects of regional analgesia techniques on cancer patients.
1. Introduction
Cancer pain poses a serious clinical and epidemiological
problem. It may be the first symptom of the disease, occurs
during its diagnosis and treatment, and accompanies pa-
tients at the advanced stages of the disease. It is estimated
that, regardless of the stage, at least one-half of cancer
patients experience pain, but their proportion is significantly
higher as the disease progresses. -e World Health Orga-
nisation (WHO) reports that over 5.5 million patients
worldwide do not receive or receive inadequate treatment
for cancer-related pain. -e above data, due to the lack of
worldwide registers, are based on epidemiological estimates
[1]. A meta-analysis published in 2016, which included 117
reports of pain in cancer patients, showed that the goal of
effective pain management still remains far from being
achieved: pain was experienced by 39.3% of patients after
radical cancer treatment, by 55% of patients during cancer
treatment, and by 66.4% at the advanced stage of cancer
treatment. 38% of patients experienced moderate to severe
pain (NRS> 5) [2].
Apart from the unimaginable suffering and the hu-
manitarian aspect of the problem, the consequences of in-
sufficiently treated pain, both acute and chronic, can also be
disastrous from a purely medical point of view. -is is
particularly important in cancer patients as more and more
data indicate a correlation between severe pain and in-
creased risk of cancer progression and a shorter time to the
appearance of metastatic lesions [3]. Research shows that
ineffective pain and stress treatment adversely affects the
body’s defence systems, including cellular immunity and the
functioning of the natural killer (NK) cells. Andersen et al.
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demonstrated that the stress associated with the diagnosis
and surgical treatment of breast cancer in women impaired
their immune cell response, including NK cell toxicity and
T-cell responses. Stress levels significantly predicted lower
NK cell lysis, diminished response of NK cells to
recombinant interferon gamma, and decreased proliferative
response of peripheral blood lymphocytes to plant lectins
and to a monoclonal antibody directed against the T-cell
receptor [4].
Experimental and clinical studies demonstrate the im-
portance of effective pain management also in terms of
cancer progression. Page et al. found a longer time interval to
lung metastasis in a group of experimental animals (rats in
the experimental model of breast adenocarcinoma) with
effective analgesia (intrathecal or systemic opioids) com-
pared with a group of animals not subject to analgesic
treatment [5]. Lillemoe et al. in their randomised prospective
study (RCT), which included a group of patients with ad-
vanced pancreatic cancer, concluded that alcohol-induced
visceral neurolysis (neurolytic splanchnicectomy) per-
formed in one of the two groups of patients provided not
only pain relief but also longer survival time, compared with
the group of patients given saline instead of alcohol. -ere
was no improvement in overall survival (OS) compared with
the control group of patients who underwent the same
procedure but who did not experience pain prior to its
onset [6].
Opioids are being used by the anaesthesiologists not only
to treat acute pain in the perioperative period but also to
control chronic cancer pain. Studies conducted over the
recent years have given results indicating the potentially
immunosuppressive effects of opioids and their serious
consequences, including the risk of cancer progression. -is
is a very important and complex problem both in peri-
operative period and in chronic pain treatment course.
Morphine has immunosuppressant properties which can
promote cancer, but on the other hand suppressing of pain
alleviates the surgical stress and thus might be protective
against tumour metastases.
2. Opioids and Their Receptors
Pharmacotherapy constitutes the basic pain treatment
method in cancer patients. For moderate to severe pain in
cancer patients, the mainstay of the therapy is opioid an-
algesics (weak or strong ones, depending on pain severity).
-ese drugs exert their clinical effects by influencing indi-
vidual opioid receptors, which are currently classified into
three groups: MOP (µ, mu), DOP (σ, delta), and KOP (κ,
kappa). Opioids can also affect other receptors, especially
NOPs (nonclassical nociceptin/orphanin FQ receptor,
N/OFQ). In everyday practice, depending on the type of pain
(receptor: somatic and visceral or neuropathic), the clinical
condition of the patient, the coexisting diseases, and ca-
pacities of organs crucial for drug metabolism and excretion
(liver and kidneys), different opioids are used, including
morphine, oxycodone, hydromorphone, fentanyl, bupre-
norphine, tapentadol, methadone, tramadol, codeine; the
last two are being classified as the so-called “weak” opioids.
Owing to the steadily increasing use of opioids, their
potential side effects are being studied in more depth. In
recent years, a number of studies have suggested immu-
nosuppressive effects of opioid analgesics and their potential
serious consequences, including an increased risk of cancer
progression in patients treated with these drugs [3].
Classically, three opioid receptor types (µ, σ, and κ) have
been identified on the central and peripheral nervous system
neurons. Moreover, based on the analysis of mRNA, re-
ceptor protein, or opioid binding capacity of cells or their
opioid response, it has been confirmed that opioid receptors
are also present on other cells, including cancer cells [7].
Interestingly, it has been shown that, by influencing the
proliferation and apoptosis processes, opioids can regulate
the growth and activity of a number of cells, including the
cancer cells [8].-is may result in an increased risk of cancer
progression. However, the test results are ambiguous as they
depend on the type of cell tested, the dosage, the time of
administration, and the type of opioid used. -e question
remains whether the direct effect of opioids on cancer cells
observed in experimental studies translates into comparable
effects in vivo and how opioids ultimately affect the immune
system status of cancer patients.
3. Potential Mechanisms of Opioid-
Induced Immunosuppression
-e immune system plays a key role in cancer defence. Its
important components include NK (natural killer cells),
T cells, mast cells, macrophages and mediators, including
cytokines (interleukins and chemokines). It turns out that
acute and chronic administration of exogenous opioids
affects both the cellular and humoral components of the
immune response. Exogenous opioids affect several of the
components of the immune system, including lymphocyte
proliferation, their phagocytic activity, NK cell activity,
cytokine expression, and antibody production [9]. Several
mechanisms responsible for immunosuppression associated
with the use of opioids in cancer patients have been iden-
tified. -ey can be divided into central and peripheral ones
and are schematically presented in Figure 1.
-e importance of central mechanisms is demonstrated
by the fact that opioids that easily penetrate the blood-brain
barrier have a stronger immunosuppressive effect compared
with those that do not pass through it—the latter demon-
strates this effect only after central administration [10].
Moreover, it turned out that MOP knockout mice did not
show any immune-modulating effect after central admin-
istration of morphine in experimental studies. -is confirms
the view that central immune modulatory effects of opioids
are mediated by the MOP receptor [11]. A central site for
opiate action in the induction of immunosuppression ap-
pears to be the periaqueductal gray matter (PAG) which also
subserves a variety of diverse autonomic functions. Mi-
croinjections of morphine into the PAG result in a rapid
suppression of natural killer (NK) cell activity [12].
-e peripheral mechanisms most likely involve the ac-
tivation of MOP opioid receptors located on immuno-
competent cells [13]. Opioid receptors have been identified
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on the surface of several types of immune system cells,
includingmultinuclear leukocytes, macrophages, Tcells, and
splenocytes [9]. Opioids added directly to certain types of
immune cells in vitro change the protein expression prole [14]
and their function: they reduce macrophage chemotaxis and
phagocytosis and weaken B-cell proliferation and antibody
production [15]. In contrary to exogenous opioids, data on
endogenous opioids are not clear, and however there are some
studies suggesting the immunostimulating e­ect. Mathews
et al. showed an increase in NK cells activity in response to
beta-endorphin, which was reversible by naloxone [16].
A number of potential mechanisms of opioid-induced
immunosuppression have been identied in experimental
studies. It turns out that these drugs may reduce the number
of macrophages available to ght infections [17] and weaken
leucocyte migration as well as and peritoneal macrophage
phagocytosis [18]. ey may also interfere with respiratory
burst activity, chemotaxis and superoxide production from
neutrophils and macrophages [19], and immune cell re-
cruitment to the wound site, which, in turn, may lead to
impaired wound healing [20]. Studies show that opioids may
also impair leucocyte endothelial adhesion by weakening
intracellular adhesion molecules [21] and intensifying the
apoptosis of macrophages [22] and Tcells [23], which results
in the impairment of the host defence barrier.
A number of mechanisms via which opioids impair
adaptive immunity have also been studied. It turns out that
these drugs may impair the T-cell viability and their pro-
liferative response [9], T-helper cell function, and macro-
phage activity [9]. Moreover, opioids may also adversely
a­ect humoral immunity by impairing primary antibody
response (B cells) [24] and B-cell mitogenic response to
bacterial liposaccharides (LPS) [25].
Another potential opioid-induced immunosuppression
pathway is the hypothalamic-pituitary-adrenal (HPA) axis:
the corticotrophin releasing hormone (CRH) stimulates the
anterior part of the pituitary gland to produce adrenocor-
ticotrophic hormone (ACTH), which, in turn, activates the
adrenal cortex to produce glucocorticoids. e latter in-
uences various components of the innate and adaptive
immune system, suppresses cellular immunity, and con-
tributes to the tolerance of various antigens by altering
T- and B-cell function [26]. e e­ects of opioids on the
HPA axis and its components (ACTH and glucocorticoids)
are complex, species dependent, and time dependent and
vary after acute and chronic administration [26]. Studies
show that, in humans, acute administration of opioids re-
sults in a reduction or no change in ACTH or glucocorticoid
levels [27]. On the contrary, chronic opioid administration
may suppress the HPA, which may lead to adrenal in-
suciency [10, 27]. Case reports have documented adrenal
insuciency after oral [28] or transdermal [29] opioid
application. Additionally, chronic opioid injections are
usually accompanied by disturbances in the daily rhythm of
ACTH and cortisol secretion [27].
Studies have shown that opioids also a­ect the sympa-
thetic system and by activating it, may cause immunosup-
pression. It is manifested, among others, by depressed NK
cell activity and suppressed peripheral blood lymphocyte
proliferation [30]. Felten et al. examined and described the
contribution of the sympathetic system to the alteration of
opioid-induced immune function and concluded that the
phenomenon is caused by the rich sympathetic innervation
of lymph nodes [31]. Other studies also validate this
mechanism by indicating that the immune status is changed
by opioids following sympathetic activation results from the
µ opioid receptors
on peripheral 
white blood cells
Opioid Brain
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Figure 1: Potential mechanisms of immunosuppressive e­ects of opioids [13].
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rich adrenergic innervation of the spleen, lymph nodes, and
bone marrow [30]. Moreover, both α and β adrenergic re-
ceptors have been identified in experimental studies
on lymphocytes and macrophages in rodents [32].
Not all opioid drugs share the same immune profile.
Some opioids seem to have no effects on immune function,
whereas others tend to be immunosuppressive. -is is
probably due to the combination of direct effects on
immunocytes and indirect effects in vivo that involve cen-
trally mediated mechanisms as well as the systemic pro-
duction and release of immunomodulatory mediators.
Studies suggest that morphine has the highest immuno-
suppressive potential, fentanyl ranks medium, while
buprenorphine and tramadol show the lowest or no im-
munosuppressive effect [33]. Morphine, codeine, and fen-
tanyl suppress NK cell activity [3]. Hydromorphone and
oxycodone, unlike morphine and fentanyl, do not impair the
immunological functions, although they are more potent
opioids than morphine [34]. Buprenorphine, which is
a partial MOP opioid receptor agonist, has no immuno-
suppressive effect and does not impair the activity of NK
cells and, hence from the immunological point of view, it is
the safest opioid [35].
A list of opioids broken down by the degree of the
immunosuppressive effect they induce is given in Table 1.
4. How Can Surgery and Perioperative Opioids
Contribute to Cancer Progression?
Several possible mechanisms which are jointly responsible
for cancer progression in the perioperative period have been
identified. Numerous studies have confirmed that surgical
manipulation, tumour dissection, and resection cause cancer
cells to migrate to the cardiovascular system and their
subsequent spread throughout the body [36]. Additionally,
surgical intervention activates and intensifies the pro-
liferation of neoplastic cells, inhibits their apoptosis [37],
and stimulates their mobility, invasiveness, and adhe-
sion—features considered very important in terms of the
capacity of neoplastic cells to reach distant organs and
metastasize [38]. It also promotes angiogenesis and net-
working of blood vessels, which offer cancer cells a kind of
pathway to the host cardiovascular system and then further
to the metastatic sites. -e mechanism of neoplastic neo-
angiogenesis involves the vascular endothelial growth factor
(VEGF), whereas other mediators, such as matrix metal-
loproteinases (MMPs), intensify adhesion and aid cancer
cells in settling in distant organs [39].
-e findings also suggest that the choice of the surgical
technique also appears to be important. Less invasive op-
tions, including laparoscopic ones, demonstrate a less in-
tense immunosuppressive effect compared with laparotomy
[40]. Other factors of proven significance in increasing the
risk of cancer progression are perioperative blood loss and
blood product transfusions, especially kept in long-term
storage [41], and hypothermia, which leads to intensified
glucocorticosteroid secretion as well as impaired cellular and
humoral immune response [42].
Stress and pain, unfortunately often experienced by
patients in the perioperative period, also constitute im-
portant factors. -ey lead to stress hormone bursts and
impair cellular immunity, including NK cell activity [43, 44].
-e most important known factors responsible for cancer
progression in the perioperative period are listed in Table 2.
Numerous studies suggest that opioids may promote
cancer progression. -e main mechanisms responsible for
this adverse effect include the stimulation of angiogenesis
and immunosuppression. Opioids, by activating MOP (µ)
opioid receptors located on vascular endothelial cells, ac-
tivate and promote angiogenesis and networking of new
blood vessels, which play an important role in the transfer of
cancer cells from the primary lesion site to the host car-
diovascular system and further to the metastatic lesion sites.
-is mechanism involves, among other things, the vascular
endothelial growth factor (VEGF) [33, 45]. Studies by
Lennon et al. have confirmed that opioids stimulate the
migration and proliferation of endothelial cells, including
vascular endothelial cells via the vascular endothelial growth
factor (VEGF) [46]. -is mechanism involves the MOP (µ)
receptor, since the administration of methylnaltrexone,
which is a peripheral antagonist of the MOP receptor, re-
duces angiogenesis. Moreover, methylnaltrexone adminis-
tered in combination with bevacizumab, which is an anti-
VEGFmonoclonal antibody, shows synergy in the inhibition
of VEGF-induced angiogenesis [47]. Gupta et al. have shown
that breast cancer cells implanted into mice grow and
multiply much faster and show intensive neovascularization
after the experimental animals have been exposed to mor-
phine [48].
Opioids may lead to progressive immunosuppression via
many of the mechanisms described in the previous part of
the article. Studies show that fentanyl, an opioid frequently
used intraoperatively, blocks the cytotoxic effect of NK cells
in the postoperative period, whereas sufentanyl and alfen-
tanyl, apart from their effect on NK cells, further weaken
mitogen-induced lymphocyte multiplication [49]. Figure 2
shows the most important mechanisms of opioid-induced
cancer progression.
5. Perioperative Setting: Possible Benefits of
Regional Analgesia and
Multimodal Analgesia
-e increasing awareness of the immunosuppressive
properties of opioids has prompted sustained efforts in
search of other effective, but most importantly, safer
methods of perioperative analgesic management. Regional
Table 1: Opioids and their immunosuppressive effects [33–35].
Strong immune
modulation Weak or no immune modulation
Morphine Buprenorphine (the least or noeffect)
Fentanyl Oxycodone
Sufentanyl Hydromorphone
Codeine Tramadol
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analgesia techniques raise hopes in this respect. eir
benecial mechanism of action is complex: on the one hand,
they provide e­ective analgesia, thus minimising the adverse
e­ects of pain on the body of the operated patient and
reducing the necessary doses of systemic analgesics (in-
cluding opioids), which translates into improved safety of
the therapy in terms of opioid-induced immunosuppression
and potential risk of cancer progression. On the other hand,
these techniques minimize the adverse e­ects of the surgical
procedure itself by attenuating of the metabolic, neuroen-
docrine, and cytokine stress response to surgery and re-
ducing the potential immunosuppressive and prognostic
impact of stress and surgical trauma.
A number of studies have assessed the impact of regional
analgesia techniques on cancer progression. e in-
terpretation of their ndings is dicult, since the surgical
injury itself, ine­ective pain treatment, and perioperative
stress all exhibit immunosuppressive e­ects and increase
cancer progression risk. Moreover, most studies assess the
impact of regional analgesia techniques on patients who
have additionally received general anaesthesia for surgery,
yet, as is well known, numerous anaesthetics administered
either intravenously or inhalationally also produce immu-
nosuppressive e­ects. However, it does not alter the fact that
the appropriately chosen and performed regional anaes-
thesia techniques (for a specic patient and surgical pro-
cedure) very e­ectively relieve pain and e­ectively block the
surgical trauma-induced neuroendocrine response of the
body and thus better preserves the patient’s immune status.
In a study done by Koltun et al., it has been seen that patients
receiving epidural anaesthesia during colectomy had lower
plasma levels of epinephrine and cortisol, compared to
patients receiving general anaesthesia, and also the NK cell
activity was better preserved in patients receiving regional
anaesthesia [50].
Most of the studies in question assess the inuence of
central blocks (including continuous epidural anaesthesia)
in prostate [51] and colorectal cancer surgery patients
Table 2: Perioperative factors a­ecting cancer progression.
I. Surgical factors
1. Cancer cells enter the cardiovascular system during surgical procedures, including tumour resection, and subsequently spread across
the body [36].
2. Surgical procedures activate and intensify the proliferation of cancer cells, stimulate their mobility and invasiveness, and increase their
capacity for adhesion [37, 38].
3. Surgical factors inhibit the apoptosis of cancer cells [37].
4. Angiogenesis and the network of newly created blood vessels constitute a kind of “pathway” for the transfer of cancer cells to the host
cardiovascular and further to metastatic lesion sites [39].
5. e selection of the surgical technique: less invasive techniques, including laparoscopic ones, have a less intense immunosuppressive
e­ect compared with open techniques [40].
II. e transfusion of blood and blood products, especially those kept in long-term storage [41].
III. Hypothermia leads to glucocorticosteroid burst and impaired immune cellular and humoral response [42].
IV. Stress and pain, often experienced by patients during the perioperative period, cause stress hormone bursts and impair cellular
immunity, including the activity of NK cells [43, 44].
VI. Anaesthetic management: type of anaesthesia used (general and regional), choice of drugs, especially opioids [50–55].
Stress hormones
(glucocorticoids,
catecholomines)
NK cells(i)
(ii)
(iii)
(iv)
(v)
(vi)
Apoptosis
Peritoneal macrophages phagocytosis
Peripheral blood lymphocyte proliferation
Chemotaxis and superoxide production 
from neutrophils and macrophages 
Immune cells recruitment to the wound site
Immune 
system
Surgery
Intra/
postoperative
pain
Opioids
Cancer
Angiogenesis
+
+
+
+
+ –
– –
–
+
+
+
Activation of cancer cells proliferation
Cancer cells mobility and invasiveness
Intensification of cancer cells adhesive abilities
Penetration of cancer cells into the circulation
(i)
(ii)
(iii)
(iv)
Figure 2: Perioperative immunosuppression mechanisms [16–23].
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[52, 53]. -e effects of the paraspinal block in breast cancer
patients undergoing mastectomy were also assessed [54].
-e findings of the studies are not unequivocal: some of
them suggest a positive influence of regional anaesthesia
techniques on immunological parameters (assessed differ-
ently in individual studies, e.g., VEGF, TGF-β, and IL-1β)
and on the reduction of the risk of cancer progression,
including prolonged overall survival time in patients in
whom these techniques were used, whereas other studies fail
to confirm these results [53, 55].
-e currently recommended optimal approach to pain
management is the multimodal analgesia approach, which
involves combining analgesics and anaesthetic techniques
with different mechanisms of action in order to take ad-
vantage of their synergistic effects. One of the components of
multimodal analgesia are regional anaesthesia techniques:
continuous epidural anaesthesia, paraspinal blocks, plexus
blocks, and interfascial blocks which are increasingly often
used in everyday clinical practice, thanks to the recent de-
velopments in ultrasonography. In the event of contraindi-
cations to regional anaesthesia techniques, combination
pharmacotherapy involving nonopioid drugs and coanalge-
sics is a recommended analgesic management method
(e.g., with intravenous lidocaine, magnesium, dexametha-
sone, ketamine, and dexmedetomidine). Such an approach,
thanks to the combination of drugs with different mecha-
nisms of action, ensures satisfactory analgesia at lower
opioid doses, which is an important aspect of safety of the
latter group of drugs referred to a number of times in this
paper. Experimental studies show that NSAIDs adminis-
tered together with opioids reduce immunosuppression
associated with the use of the latter [54]. However, it should
be remembered that the use of NSAIDs is subject to
a number of restrictions due to the risk of gastrointestinal
and renal damage, increased cardiovascular risk, and in-
creased risk of bleeding secondary to the antiplatelet effect of
nonselective NSAIDs. However, these drugs are worth
considering as therapeutic options in cancer patients (taking
into account the contraindications to their use), especially
due to the NSAIDs’ preventive effect on certain types of
cancer and the possible anticancer effect of this group of
drugs [56].
It should also be emphasized that the development of
effective therapeutic strategies requires a better un-
derstanding of cellular mechanisms underlying the patho-
genesis of pain. Progress in pain research points to an
important role of microglial cells in the development of pain.
-e inhibition of spinal microglia has been shown to at-
tenuate postoperative pain as well as morphine-induced
antinociceptive tolerance [57]. Targeting microglial signal-
ing might lead to more effective treatments for pain partly
via improving the analgesic efficacy of opioids [58–60].
6. Conclusions
Insufficiently treated pain and stress associated with cancer
adversely affect the body’s defence mechanisms, including
cellular immunity, natural killer (NK) cell function, and
humoral response. Experimental and clinical studies
also show the importance of effective pain management
for checking cancer progression. Apart from the basic hu-
manitarian aspect, these data provide an argument for the
need to effectively alleviate stress and suffering in cancer
patients. -e question of how to do it optimally and in the
safest possible way is still relevant, given the substantial
evidence concerning the potentially adverse opioid effects to
have emerged in recent studies (including immunosup-
pression, increased risk of infection, and cancer
progression).
It should be clearly emphasized that the findings of
research on the latter issue are ambiguous and as such
should be treated with great caution. -ey must not be
interpreted as an argument against using opioids in pain
management in cancer patients. Effective pain treatment,
alleviation of suffering associated with cancer, and im-
provement in the quality of life should always be a priority,
while the awareness of potential risks should prompt the use
of regional analgesia techniques, using local analgesics and
possibly coanalgesics. Where it is impossible, recommen-
dations include combined systemic pharmacotherapy
comprising nonopioid analgesics and coanalgesics, some of
which (including lidocaine and NSAIDs) also exhibit proven
oncologically beneficial effects. Such an approach contrib-
utes to the optimization of analgesic management, and thus
to obtaining the best analgesic effects at lower opioid doses,
which, in turn, reduces the frequency and intensity of ad-
verse effects associated with their use. Further research is
needed to verify the currently available data on both the
potential adverse effects of opioids and the possible pro-
tective effects of regional analgesia techniques on cancer
patients.
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